Back to results
US 2019/0082845 A1Published application
Carbazole compounds and therapeutic uses of the compounds
AssigneeIncuron, LLC
InventorsJohn TUCKER, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
Life of this patent
Estimating the term…
Abstract
Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
Claims21
A compound having a structural formula:
- wherein Ra is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, ORe, N(Re)2, and SRe;
- alternatively, either Ra and R1 or NRe and R1 together with the carbon atoms to which they are attached form a five or six-membered aliphatic carbocyclic or heterocyclic ring;
- Rb is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, ORe, N(Re)2, and SRe, alternatively, either Rb and R6 or NRe and R6 together with the carbon atoms to which they are attached form a five or six-membered aliphatic carbocyclic ring or a five or six-membered aliphatic carbocyclic or heterocyclic ring;
- Rc is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Re, or Rc and Rd are taken together to form a five, six, or seven-membered aliphatic ring, optionally containing an oxygen atom;
- Rd is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Re, or Rd and R7 together with the atoms to which they are attached form a five or six-membered aliphatic ring;
- Re, independently, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, or two Re groups taken together with a nitrogen to which they are attached to form a five or six-membered aliphatic ring;
- R1, R2, R3, R4, R5, and R6, independently, are selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, ORe, C(═O)Re, C(═O)ORe, OC(═O)Re, C(═O)N(Re)2, C(═O)NReSO2Re, N(Re)2, NReC(═O)Re,
- ReC(═O)N(Re)2, CN, NO2, CF3, OCF3, SRe, SORe, SO2Re, SO2N(Re)2, and OSO2CF3;
- R7 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
- and
- n is 0, 1, 2, 3, 4, or 5,
- or a pharmaceutically acceptable salt or hydrate thereof.
9 more elements
A compound having a structural formula:
- wherein R1 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Rh, or Rf and Rg are taken together to form a five, six, or seven-membered aliphatic ring optionally containing an oxygen atom;
- R8 is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and C(═O)Rh, or Rg and R8 together with the atoms to which they are attached form a five or six-membered aliphatic ring;
- Rh, independently, is selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, or two Rh groups taken together with a nitrogen to which they are attached to form a five or six-membered aliphatic ring;
- R8 is selected from the group consisting of hydrogen, C 1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
- R9, R10, R11, R12, R13, and R14, independently, are selected from the group consisting of hydrogen, C1-6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, ORh, C(═O)Rh, C(═O)ORh, OC(═O)Rh, C(═O)N(Rh)2, C(═O)NRhSO2Rh, N(Rh)2, NReC(═O)Rh, NRhC(═O)N(Rh)2, CN, NO2, CF3, OCF3, SRh, SORh, SO2Rh, SO2N(Rh)2, and OSO2CF3;
- p is 0, 1, 2, 3, 4, or 5,
- with the proviso that when p is 2, one of Rf and Rg is different from ethyl,
- or a pharmaceutically acceptable salt or hydrate thereof.
5 more elements
A compound having a structure formula:
A compound selected from the group disclosed in paragraph [0238] herein.
A method of treating a disease or condition selected from the group consisting of the diseases and conditions disclosed in paragraph [0278] herein.
Dependencies are inferred from the claim text.